logo-loader
RNS
viewe-Therapeutics PLC

e-Therapeutics plc - Retail Offer

RNS Number : 3125S
e-Therapeutics plc
07 July 2020
 

EMBARGOED FOR ON 7 JULY 2020.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014.

THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF E-THERAPEUTICS PLC.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT (EACH A "RESTRICTED JURISDICTION").

THIS ANNOUNCEMENT AMOUNTS TO A FINANCIAL PROMOTION FOR THE PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 ("FSMA") AND HAS BEEN APPROVED BY PRIMARYBID LIMITED WHICH IS AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY (FRN 779021)

 

7 July 2020

 

e-therapeutics plc

 

("e-therapeutics" or the "Company")

 

Retail Offer

 

e-therapeutics plc (AIM: ETX.L) is pleased to announce a conditional offer for subscription via PrimaryBid (the "Retail Offer") of new ordinary shares of 0.1p each in the Company ("Retail Shares") at an issue price of 12 pence per New Ordinary Share (the "Issue Price"), being a discount of 30.9 per cent to the closing mid-price of 17.4 pence per New Ordinary Share on 6 July 2020, being the latest practicable date prior to the time and date of this announcement.

The Company is also conducting a placing of new Ordinary Shares at the Issue Price by way of a firm placing by Numis Securities Limited (the "Firm Placing"), an associated broker option in the event of additional demand (the "Broker Option"), and direct subscriptions with the Company by individual investors based in various overseas jurisdictions (the "Subscription"), as announced on 7 July 2020.

The PrimaryBid Offer, the Subscription and the Firm Placing are conditional on the new Ordinary Shares to be issued pursuant thereto being admitted to trading on the AIM market of the London Stock Exchange ("Admission"). Admission is expected to be take place at 8.00 a.m. on 15 July 2020. The Retail Offer will not be completed without the Firm Placing also being completed.

The Company will use the funds raised to facilitate a number of initiatives to enable the Company's next stage of growth and value creation by expanding the Company's platform capabilities and asset pipeline.

 

Retail Offer

The Company values its retail investor base and is therefore pleased to provide private and other investors the opportunity to participate in the Retail Offer by applying exclusively through the www.PrimaryBid.com platform and the PrimaryBid mobile app available on the Apple App Store and Google Play.

The Retail Offer, via the PrimaryBid.com platform, will be open to individual and institutional investors from 4.45 p.m. to 9 p.m. on 7 July 2020. The Retail Offer may close early if it is oversubscribed.

Subscriptions under the Retail Offer will be considered by the Company on a "first come, first served" basis, although preference to be given to the Company's existing shareholders, subject to conditions which are available to view on PrimaryBid.com.

The Company in consultation with PrimaryBid reserves the right to scale back any order at its discretion. The Company and PrimaryBid reserve the right to reject any application for subscription under the Retail Offer without giving any reason for such rejection.

No commission is charged to investors on applications to participate in the Retail Offer made through PrimaryBid.  It is vital to note that once an application for Retail Shares has been made and accepted via PrimaryBid, an application cannot be withdrawn.

For further information on PrimaryBid.com or the procedure for applications under the Retail Offer, visit www.PrimaryBid.com or call PrimaryBid.com on +44 20 3026 4750. 

The Retail Shares will be issued free of all liens, charges and encumbrances and will, when issued and fully paid, rank pari passu in all respects with the Company's existing Ordinary Shares.

e-therapeutics plc

Ali Mortazavi, Executive Chairman

Laura Roca-Alonso, Chief Business Officer

 

 

+44 (0)1993 883 125

www.etherapeutics.co.uk 

PrimaryBid Limited

Kieran D'Silva / James Deal

+ 44 (0) 203 026 4750

 


 

FTI Consulting

Simon Conway/Stephanie Cuthbert

 

 

 

+44 (0) 203 727 1000

[email protected]

Details of the Retail Offer

The Company values its retail investor base which has supported the Company alongside institutional investors over several years. Given the longstanding support of retail shareholders, the Company believes that it is appropriate to provide retail and other interested investors the opportunity to participate in the Retail Offer. The Company is therefore offering the Retail Shares through PrimaryBid.com.

The Retail Offer is being made pursuant to an exemption from the requirement to publish a prospectus allowed under the Prospectus Rules. As such, there is no need for publication of a prospectus pursuant to the Prospectus Rules, or for approval of the same by the Financial Conduct Authority. The Retail Offer is not being made into any Restricted Jurisdiction.

There is a minimum subscription of £100 per investor under the terms of the Retail Offer which is open to existing shareholders and other investors subscribing via PrimaryBid.com. This allocation will be filled on a "first come first served" basis, although preference will be given to existing shareholders.

For further details please refer to the PrimaryBid.com website at www.PrimaryBid.com. The terms and conditions on which the Retail Offer is made, including the procedure for application and payment for Retail Shares, is available to all persons who register with PrimaryBid.com.

Investors should make their own investigations into the merits of an investment in the Company. Nothing in this announcement amounts to a recommendation to invest in the Company or amounts to investment, taxation or legal advice.

It should be noted that a subscription for Retail Shares and investment in the Company carries a number of risks. Investors should consider the risk factors set out on PrimaryBid.com before making a decision to subscribe for Retail Shares. Investors should take independent advice from a person experienced in advising on investment in securities such as the Retail Shares if they are in any doubt. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
IOERRMFTMTJMBLM

Quick facts: e-Therapeutics PLC

Price: 13.625

Market: AIM
Market Cap: £57.1 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE